Cargando…
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
Aim: To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. Patients and Methods: Recurrent ovarian cancer patients (n = 21) enrolled in prior clinical trials. Results: GEP stratified by TIS(HIGH) vs. TIS(LOW) demon...
Autores principales: | Rocconi, Rodney P., Stanbery, Laura, Madeira da Silva, Luciana, Barrington, Robert A., Aaron, Phylicia, Manning, Luisa, Horvath, Staci, Wallraven, Gladice, Bognar, Ernest, Walter, Adam, Nemunaitis, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402348/ https://www.ncbi.nlm.nih.gov/pubmed/34452019 http://dx.doi.org/10.3390/vaccines9080894 |
Ejemplares similares
-
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
por: Barve, Minal, et al.
Publicado: (2022) -
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2022) -
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
por: Oh, Johnathan, et al.
Publicado: (2020) -
Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2023) -
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
por: Barve, Vedin, et al.
Publicado: (2021)